Data-Backed Celltrion Looks To File Xolair Biosimilar ‘This Year’
Bumper Year Planned, With Up To Five Filings On Company’s Agenda
Likely frontrunner Celltrion has published 24-week Phase III data for its CT-P39 biosimilar Xolair candidate, which tees up a planned biosimilar filing later this year.
